[go: up one dir, main page]

ATE547108T1 - Schutz gegen die neurotoxizität des oxaliplatins durch verabreichung von kalzium und magnesium - Google Patents

Schutz gegen die neurotoxizität des oxaliplatins durch verabreichung von kalzium und magnesium

Info

Publication number
ATE547108T1
ATE547108T1 AT03712239T AT03712239T ATE547108T1 AT E547108 T1 ATE547108 T1 AT E547108T1 AT 03712239 T AT03712239 T AT 03712239T AT 03712239 T AT03712239 T AT 03712239T AT E547108 T1 ATE547108 T1 AT E547108T1
Authority
AT
Austria
Prior art keywords
calcium
magnesium
administration
neurotoxicity
oxaliplatin
Prior art date
Application number
AT03712239T
Other languages
English (en)
Inventor
Laurence Gamelin
Erick Gamelin
Michele Boisdron-Celle
Alain Morel
Original Assignee
Ct Regional De Lutte Contre Le Cancer D Angers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Regional De Lutte Contre Le Cancer D Angers filed Critical Ct Regional De Lutte Contre Le Cancer D Angers
Application granted granted Critical
Publication of ATE547108T1 publication Critical patent/ATE547108T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03712239T 2002-01-14 2003-01-14 Schutz gegen die neurotoxizität des oxaliplatins durch verabreichung von kalzium und magnesium ATE547108T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0200390A FR2834641B1 (fr) 2002-01-14 2002-01-14 Protection de la neurotoxicite de l'oxaliplatine par administration de calcium et de magnesium
PCT/FR2003/000098 WO2003059361A1 (fr) 2002-01-14 2003-01-14 Protection de la neuritoxicité de l'oxaliplatine par administration de calcium et de magnésium

Publications (1)

Publication Number Publication Date
ATE547108T1 true ATE547108T1 (de) 2012-03-15

Family

ID=8871278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03712239T ATE547108T1 (de) 2002-01-14 2003-01-14 Schutz gegen die neurotoxizität des oxaliplatins durch verabreichung von kalzium und magnesium

Country Status (9)

Country Link
US (1) US20050148661A1 (de)
EP (1) EP1465642B1 (de)
JP (1) JP4629340B2 (de)
AT (1) ATE547108T1 (de)
AU (1) AU2003216720A1 (de)
DK (1) DK1465642T3 (de)
ES (1) ES2382517T3 (de)
FR (1) FR2834641B1 (de)
WO (1) WO2003059361A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103344A1 (en) * 2003-05-20 2004-12-02 Aronex Pharmaceuticals, Inc. Combination chemotherapy comprising a liposomal platinum complex
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
KR20200099172A (ko) 2018-01-12 2020-08-21 (주) 메티메디제약 만성 염증성 질환의 치료 방법
CN109596818B (zh) * 2018-12-13 2024-03-19 丁蓉 一种基于电生理学分析当归四逆汤预防奥沙利铂神经毒性机制的研究方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE123306T1 (de) * 1989-05-19 1995-06-15 Hayashibara Biochem Lab Alpha-glycosyl-l-ascorbinsäure und ihre herstellung und verwendungen.
AU4597293A (en) * 1992-06-30 1994-01-24 Procter & Gamble Company, The Effervescent calcium supplements
US5698222A (en) * 1995-04-07 1997-12-16 Abbott Laboratories Calcium supplement
RU2268054C2 (ru) * 1999-07-29 2006-01-20 Амджен Инк. Сочетанная терапия с использованием пентафторбензолсульфонамидов
AU2001240001A1 (en) * 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi

Also Published As

Publication number Publication date
FR2834641B1 (fr) 2005-04-22
AU2003216720A1 (en) 2003-07-30
ES2382517T3 (es) 2012-06-11
JP2005519062A (ja) 2005-06-30
FR2834641A1 (fr) 2003-07-18
DK1465642T3 (da) 2012-05-07
WO2003059361A1 (fr) 2003-07-24
EP1465642A1 (de) 2004-10-13
US20050148661A1 (en) 2005-07-07
JP4629340B2 (ja) 2011-02-09
EP1465642B1 (de) 2012-02-29

Similar Documents

Publication Publication Date Title
MX2008000915A (es) Tratamiento con inhibidores de absorcion de colesterol basados en azetidinona y acidos grasos omega-3 y un producto de combinacion de los mismos.
TW200630093A (en) Dose forms
ZA202108632B (en) Tricyclic akr1c3 dependent kars inhibitors
MXPA05008368A (es) 1,2,4-triazinas inhibidoras del virus de inmunodeficiencia humana.
PH12016500933A1 (en) Novel combination treatment for acute myeloid leukemia (aml)
MY140840A (en) Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
MX2009003928A (es) Tratamiento con antiarritmicos y acidos grasos omega-3 y un producto de combinacion de los mismos.
TW200745103A (en) Substituted 7-azaindazoles, compositions containing them, production process and use
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
MXPA05009601A (es) Dispositivos de distribucion.
MX2019008917A (es) Composiciones farmaceuticas para terapia de combinacion.
HK1114769A1 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
TW200634007A (en) Substituted indoles, compositions containing them, production process and use
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
ATE547108T1 (de) Schutz gegen die neurotoxizität des oxaliplatins durch verabreichung von kalzium und magnesium
TN2009000119A1 (en) Combination drug
MD4615B1 (ro) Formă solidă izolată de monoclorhidrat de anamorelin, compoziţie farmaceutică şi procedeu de fabricare a formei de dozare farmaceutice care o conţine
HRP20080422T3 (en) Satraplatin for treating resistant or refractory tumors
EP1682565A4 (de) Iap-nukleobase-oligomere und oligomere komplexe und anwendungen davon
MX2015009348A (es) Composiciones hemostaticas.
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
NO20085267L (no) Derivater av 2-alkoksy -3,4,5-trihydroksy-alkyl amider, fremstilling og anvendelse derav, samt sammensetninger inneholdende samme
TNSN08442A1 (en) 2-alkoxy-3,4,5-trihydroxy-alkylamide-benzothiazepines, the preparation and use thereof, and compositions containing the same
TH112630A (th) ยาบำบัดรักษามะเร็งตับ
HUP0300682A2 (hu) Dalfopristin/kinupristin kombinációit cefpirommal együtt tartalmazó gyógyszerkészítmények